Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel therapeutics leveraging CRISPR-based technologies with two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine.
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth! No
ACC.23 Learning Pathways? (select all that apply) Heart Failure and Cardiomyopathies
First time Exhibitor? Yes